Holen Sie sich die Stockscreener-App
7.7467
0.52%
0.0167
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Is Cybin Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com
What analysts say about Cybin Inc. stockOutstanding risk-reward balance - jammulinksnews.com
Cybin Inc. Stock Analysis and ForecastFree Stock Selection - jammulinksnews.com
(CYBN) Proactive Strategies - news.stocktradersdaily.com
High-Risk, High-Reward Stocks With Serious Momentum: 5 Stocks to Consider - AInvest
Cybin Inc: CYB003 Phase 3 Program Continues to Progress on Plan - Smartkarma
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
What drives Cybin Inc. stock priceBreakthrough financial growth - jammulinksnews.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - Yahoo Finance
UK MHRA approves Cybin’s trial of CYB003 for major depressive disorder - Yahoo Finance
Three High-Risk, High-Reward Stocks in AI, Biotech, and Autonomous Vehicles - AInvest
Cybin's EMBRACE Study: A Pivotal Step in Psychedelic-Driven Mental Healthcare Innovation - AInvest
Cybin receives UK MHRA approval to commence EMBRACE study - TipRanks
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Cybin Secures UK Approval for Pivotal Depression Study - TipRanks
Cybin receives UK approval for second pivotal depression study By Investing.com - Investing.com South Africa
Cybin receives UK approval for second pivotal depression study - Investing.com Australia
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Yahoo Finance
3 High-Risk, High-Reward Stocks With Explosive Upside - MarketBeat
Three High-Risk, High-Reward Stocks with Explosive Upside: Rezolve AI, Aurora Innovation, and Cybin Inc. - AInvest
Cybin, Inc.CYB003 Vs. Other Aspiring Novel Depression Treatments - Smartkarma
Cybin Inc. Expands Market Strategy with New SEC Filing - The Globe and Mail
Cybin, Inc: Not All Psychedelic Treatments for Depression Are Created Equal - Smartkarma
Cybin Inc. Secures $50 Million in Convertible Debenture Deal - The Globe and Mail
(CYBN) Investment Analysis - news.stocktradersdaily.com
Cybin: Upgrade To HoldBut Don't Get Too Carried Away (NYSE:CYBN) - Seeking Alpha
Cybin Inc. Reports on Governance and Compliance - TipRanks
Canaccord Genuity lowers Cybin stock price target to $70 on model update - Investing.com Australia
Canaccord Genuity lowers Cybin stock price target to $70 on model update By Investing.com - Investing.com South Africa
Cybin price target lowered to $70 from $73 at Canaccord - TipRanks
African psilocybin cultivator Psyence gets C$600K investment - Mugglehead Magazine
Psychedelic drug developer Cybin secures major financing deal - Mugglehead Magazine
Cybin Signs Deal With High Trail to Sell, Issue Up to $500 Million Convertible Debentures - MarketScreener
Cybin (CYBN) Reports Increased Q4 Net Loss Amid Stable Cash Flows - GuruFocus
Cybin's $500M Debt Deal: Betting Big on Psychedelic Medicine's Clinical Milestones - AInvest
Cybin Inc. Advances Mental Health Innovations with Strategic Partnerships and Clinical Progress - TipRanks
Cybin Secures $500 Million Financing to Boost Clinical Programs - TipRanks
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures | CYBN Stock News - GuruFocus
4.56%
0.49%
Kapitalisierung:
|
Volumen (24h):